Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHINTAN CHANDRAKANT GANDHI

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1568764629
CMS profile
1389089
Location
TAMARAC, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2023 · Entire year

$957.94

51 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2023 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $957.94 51

By paying entity

PY2023 · entire year · sorted by reported total

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHINTAN CHANDRAKANT GANDHI

NPI 1568764629 · CMS profile ID 1389089

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

TAMARAC, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1568764629?year=2023&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHINTAN CHANDRAKANT GANDHI, NPI 1568764629, CMS profile ID 1389089. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1568764629?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
APA 7
IndustryPayments. (2026). CHINTAN CHANDRAKANT GANDHI, NPI 1568764629, CMS profile ID 1389089. General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1568764629?year=2023&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9.
Bluebook
CHINTAN CHANDRAKANT GANDHI, NPI 1568764629, CMS profile ID 1389089, IndustryPayments, General Payments, PY2023; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–51 of 51 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb3a65aa-c901-4a38-a813-b04b00dfa2a9. https://industrypayments.org/provider/npi-1568764629?year=2023&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2023

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2023 · Physicians and non-physician practitioners · CMS publication 2026-06-30

51 matching records · $957.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 51 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–51 of 51.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Incyte Corporation $23.1901/12/2023 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1044718313 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $12.15 1
PY2020 $12.71 1
PY2021 $187.96 7
PY2022 $317.46 18
PY2023 $957.94 51
PY2024 $121.96 4
PY2025 $223.65 7

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $472,700.33 168
PY2024 Principal investigator $82,419.17 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

168 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $72.00 12/31/2025 Non-covered Recipient Entity
BRCR MED CENTER INC
A Phase 2, Open-Label Trial to Evaluate Safety of Epcoritamab Monotherapy in Subjects with Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma (Previously Grade 1-3a) when Administered in the Outpatient Setting No dispute reported 06/30/2026 1202534269
Principal investigator 1 PFIZER INC. $600.00 12/31/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228731843
Principal investigator 1 GENZYME CORPORATION $17,740.80 12/22/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091265
Principal investigator 1 GENZYME CORPORATION $50.35 12/22/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091270
Principal investigator 1 PFIZER INC. $600.00 11/14/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228715427
Principal investigator 1 Daiichi Sankyo Inc. $31.00 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364929
Principal investigator 1 Daiichi Sankyo Inc. $31.00 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364931
Principal investigator 1 Daiichi Sankyo Inc. $31.00 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364933
Principal investigator 1 Daiichi Sankyo Inc. $41.70 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364935
Principal investigator 1 Daiichi Sankyo Inc. $138.00 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364937
Principal investigator 1 Daiichi Sankyo Inc. $31.00 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364939
Principal investigator 1 Daiichi Sankyo Inc. $31.00 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364941
Principal investigator 1 Daiichi Sankyo Inc. $4.40 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364943
Principal investigator 1 Daiichi Sankyo Inc. $31.00 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364945
Principal investigator 1 Daiichi Sankyo Inc. $41.70 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364947
Principal investigator 1 Daiichi Sankyo Inc. $31.00 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364949
Principal investigator 1 Daiichi Sankyo Inc. $41.70 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364951
Principal investigator 1 Daiichi Sankyo Inc. $41.70 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364953
Principal investigator 1 Daiichi Sankyo Inc. $31.00 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364955
Principal investigator 1 Daiichi Sankyo Inc. $31.00 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364957
Principal investigator 1 Daiichi Sankyo Inc. $41.70 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364959
Principal investigator 1 Daiichi Sankyo Inc. $31.00 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364961
Principal investigator 1 Daiichi Sankyo Inc. $31.00 11/03/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364963
Principal investigator 1 Eli Lilly and Company $710.01 10/27/2025 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE LY3537021 FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN ADULT PARTICIPANTS WITH MALIGNANT DISEASE No dispute reported 06/30/2026 1187877065
Principal investigator 1 Eli Lilly and Company $22,217.00 10/06/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER
A PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO EVALUATE LY3537021 FOR THE TREATMENT OF CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING IN ADULT PARTICIPANTS WITH MALIGNANT DISEASE No dispute reported 06/30/2026 1187875511
Principal investigator 1 PFIZER INC. $660.00 08/14/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228785711
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364701
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364703
Principal investigator 1 Daiichi Sankyo Inc. $30.24 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364705
Principal investigator 1 Daiichi Sankyo Inc. $55.08 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364707
Principal investigator 1 Daiichi Sankyo Inc. $55.08 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364709
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364711
Principal investigator 1 Daiichi Sankyo Inc. $55.08 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364713
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364715
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364717
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364719
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364721
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364723
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364725
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364727
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364729
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364731
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364733
Principal investigator 1 Daiichi Sankyo Inc. $30.24 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364735
Principal investigator 1 Daiichi Sankyo Inc. $30.24 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364737
Principal investigator 1 Daiichi Sankyo Inc. $30.24 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364739
Principal investigator 1 Daiichi Sankyo Inc. $30.24 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364741
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364743
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364745
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364747
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364749
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364751
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364753
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364755
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364757
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364759
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364761
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364763
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364765
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364767
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364769
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364771
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364773
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364775
Principal investigator 1 Daiichi Sankyo Inc. $30.24 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364777
Principal investigator 1 Daiichi Sankyo Inc. $30.24 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364779
Principal investigator 1 Daiichi Sankyo Inc. $30.24 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364781
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364783
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364785
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364787
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364789
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364791
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364793
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364795
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364797
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364799
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364801
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364803
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364805
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364807
Principal investigator 1 Daiichi Sankyo Inc. $55.08 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364809
Principal investigator 1 Daiichi Sankyo Inc. $55.08 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364811
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364813
Principal investigator 1 Daiichi Sankyo Inc. $55.08 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364815
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364817
Principal investigator 1 Daiichi Sankyo Inc. $55.08 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364819
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364821
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364823
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364825
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364827
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364829
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364831
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364833
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364835
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364837
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364839
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364841
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364843
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364845
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364847
Principal investigator 1 Daiichi Sankyo Inc. $55.08 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364849
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364851
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364853
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364855
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364857
Principal investigator 1 Daiichi Sankyo Inc. $17.79 07/22/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364859
Principal investigator 1 Daiichi Sankyo Inc. $945.00 07/16/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364995
Principal investigator 1 Daiichi Sankyo Inc. $370.00 07/16/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364997
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 07/02/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364985
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 07/02/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364987
Principal investigator 1 Daiichi Sankyo Inc. $30,000.00 07/02/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364989
Principal investigator 1 Daiichi Sankyo Inc. $7,000.00 07/02/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364991
Principal investigator 1 Daiichi Sankyo Inc. $3,800.00 07/02/2025 Non-covered Recipient Entity
BRCR Global
DS8201-793 No dispute reported 06/30/2026 1223364993
Principal investigator 1 Daiichi Sankyo Inc. $750.00 06/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223365001
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,500.00 05/08/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20X ANTI-CD3 BISPECIFIC ANTIBODY, COMBINED WITH CHEMOTHERAPY VERSUS RITUXIMAB COMBINED WITH CHEMOTHERAPY IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-2) No dispute reported 06/30/2026 1184193733
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,000.00 05/08/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20X ANTI-CD3 BISPECIFIC ANTIBODY, COMBINED WITH CHEMOTHERAPY VERSUS RITUXIMAB COMBINED WITH CHEMOTHERAPY IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-2) No dispute reported 06/30/2026 1184193735
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,550.00 05/08/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20X ANTI-CD3 BISPECIFIC ANTIBODY, COMBINED WITH CHEMOTHERAPY VERSUS RITUXIMAB COMBINED WITH CHEMOTHERAPY IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-2) No dispute reported 06/30/2026 1184193737
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,100.00 05/08/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3, OPEN-LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20X ANTI-CD3 BISPECIFIC ANTIBODY, COMBINED WITH CHEMOTHERAPY VERSUS RITUXIMAB COMBINED WITH CHEMOTHERAPY IN PREVIOUSLY UNTREATED PARTICIPANTS WITH FOLLICULAR LYMPHOMA (OLYMPIA-2) No dispute reported 06/30/2026 1184193739
Principal investigator 1 Amgen Inc. $6,500.00 04/24/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors No dispute reported 06/30/2026 1246639787
Principal investigator 1 PFIZER INC. $600.00 04/08/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228778835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,500.00 04/01/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH LENALIDOMIDE VERSUS RITUXIMAB IN COMBINATION WITH LENALIDOMIDE THERAPY IN RELAPSED/REFRACTORY PARTICIPANTS WITH FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5) No dispute reported 06/30/2026 1184180852
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,000.00 04/01/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH LENALIDOMIDE VERSUS RITUXIMAB IN COMBINATION WITH LENALIDOMIDE THERAPY IN RELAPSED/REFRACTORY PARTICIPANTS WITH FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5) No dispute reported 06/30/2026 1184180872
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,100.00 04/01/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH LENALIDOMIDE VERSUS RITUXIMAB IN COMBINATION WITH LENALIDOMIDE THERAPY IN RELAPSED/REFRACTORY PARTICIPANTS WITH FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5) No dispute reported 06/30/2026 1184180874
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,550.00 04/01/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A PHASE 3, OPEN LABEL, RANDOMIZED STUDY TO COMPARE THE EFFICACY AND SAFETY OF ODRONEXTAMAB (REGN1979), AN ANTI-CD20 X ANTI-CD3 BISPECIFIC ANTIBODY, IN COMBINATION WITH LENALIDOMIDE VERSUS RITUXIMAB IN COMBINATION WITH LENALIDOMIDE THERAPY IN RELAPSED/REFRACTORY PARTICIPANTS WITH FOLLICULAR LYMPHOMA AND MARGINAL ZONE LYMPHOMA (OLYMPIA-5) No dispute reported 06/30/2026 1184180876
Principal investigator 1 Daiichi Sankyo Inc. $2,000.00 03/24/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223365003
Principal investigator 1 Daiichi Sankyo Inc. $30,000.00 03/24/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223365005
Principal investigator 1 Daiichi Sankyo Inc. $2,500.00 03/24/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223365007
Principal investigator 1 Daiichi Sankyo Inc. $3,200.00 03/24/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223365009
Principal investigator 1 Daiichi Sankyo Inc. $3,400.00 03/24/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223365011
Principal investigator 1 GENZYME CORPORATION $48,016.00 03/24/2025 Non-covered Recipient Entity
Brcr Medical Center Inc
A Single-arm, Open-label, Phase 2 Study Evaluating Subcutaneous Administration of Isatuximab, Administered by an On Body Delivery System, in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) No dispute reported 06/30/2026 1226091379
Principal investigator 1 PFIZER INC. $600.00 03/14/2025 Non-covered Recipient Entity
BRCR Medical Center Inc
A PHASE 3 OPENLABEL STUDY OF ELRANATAMAB MONOTHERAPY VERSUS ELOTUZUMAB POMALIDOMIDE DEXAMETHASONE EPD OR POMALIDOMIDE BORTEZOMIB DEXAMETHASONE PVD OR CARFILZOMIB DEXAMETHASONE KD IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO RECEIVED PRIOR ANTICD38 DIRECTED THERAPY No dispute reported 06/30/2026 1228797748
Principal investigator 1 Amgen Inc. $6,165.00 02/22/2025 Non-covered Recipient Entity
BOCA RATON CLINICAL RESEARCH GLOBAL SOUTH FLORIDA
A Phase 1/1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 Alone and in Combination With Docetaxel in Subjects With Advanced MTAP-null Solid Tumors No dispute reported 06/30/2026 1246639751
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364869
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364871
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364873
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364875
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364877
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364879
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364881
Principal investigator 1 Daiichi Sankyo Inc. $75.00 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364883
Principal investigator 1 Daiichi Sankyo Inc. $6.60 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364885
Principal investigator 1 Daiichi Sankyo Inc. $46.50 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364887
Principal investigator 1 Daiichi Sankyo Inc. $257.75 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364889
Principal investigator 1 Daiichi Sankyo Inc. $4.25 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364891
Principal investigator 1 Daiichi Sankyo Inc. $9.75 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364893
Principal investigator 1 Daiichi Sankyo Inc. $138.00 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364895
Principal investigator 1 Daiichi Sankyo Inc. $85.40 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364897
Principal investigator 1 Daiichi Sankyo Inc. $50.15 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364899
Principal investigator 1 Daiichi Sankyo Inc. $41.70 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364901
Principal investigator 1 Daiichi Sankyo Inc. $41.70 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364903
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364905
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364907
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364909
Principal investigator 1 Daiichi Sankyo Inc. $41.70 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364911
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364913
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364915
Principal investigator 1 Daiichi Sankyo Inc. $41.70 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364917
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364919
Principal investigator 1 Daiichi Sankyo Inc. $31.00 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364921
Principal investigator 1 Daiichi Sankyo Inc. $41.70 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364923
Principal investigator 1 Daiichi Sankyo Inc. $41.70 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364925
Principal investigator 1 Daiichi Sankyo Inc. $74.50 02/04/2025 Non-covered Recipient Entity
BRCR Global
DS3201-330 No dispute reported 06/30/2026 1223364927
Principal investigator 1 Amgen Inc. $169,646.05 01/23/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A Randomized, Double-Blind Study to Compare Efficacy, Pharmacokinetics, Safety, and Immunogenicity Between ABP 234 and Keytruda (Pembrolizumab) in Subjects With Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer No dispute reported 06/30/2026 1246639791
Principal investigator 1 GlaxoSmithKline, LLC. $3,500.00 01/02/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192128954
Principal investigator 1 GlaxoSmithKline, LLC. $3,313.00 01/02/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192128958
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 01/02/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192128964
Principal investigator 1 GlaxoSmithKline, LLC. $23,000.00 01/02/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192128972
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 01/02/2025 Non-covered Recipient Entity
BRCR MEDICAL CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY TO EVALUA No dispute reported 06/30/2026 1192128979